Skip to content

8:30 am Chair’s Opening Remarks

  • Dora Mitchell Vice President, Business Development, Carisma Therapeutics

Macrophage Targeting Approaches

Targeting the “Don’t Eat Me Signal” to Overcome Sink Effect & Toxicity Risks

9:00 am Targeting CD47-SIRPa Myeloid Checkpoint Pathway to Enhance Innate & Adaptive Immunity Against Cancer without Hematological Toxicity

  • Hong Wan Chief Scientific Officer, ALX Oncology

Synopsis

• Discuss how ALX148, a unique CD47 blocker which is a high affinity SIRPa fusion protein linked to an inactive Fc region of human immunoglobulin, is designed to maximize the clinical benefit of antibody-based therapies and its clinical development for a broad range of tumor types
• Review preclinical studies where ALX148 bridges innate and adaptive immunity via Fc-dependent and Fc-independent mechanisms to enhance anti-tumor response in combination with targeted anti-cancer antibodies and checkpoint inhibitors with no adverse effect on CD47-expressing normal blood cells
• Understand how ALX148 is well tolerated and demonstrates antibody-like PK and complete CD47 target occupancy in cancer patients
• Discuss anti-cancer activity and translational results from Phase 1 program

9:30 am Safety, Tolerability & Efficacy of CD47 Monoclonal Antibodies in Advanced Malignancies

  • Junjian Liu Vice President, Head of Drug Discovery & Preclinical Development, Innovent Biologics

Synopsis

• Discovery of IBI188, a fully human anti-CD47 therapeutic antibody
• Outline preliminary Phase 1 clinical trial results which explore recommended doses for IBI188 in combination
• Discuss future direction in CD47 blockade

10:00 am Using Digital Pathology Tools to Solve the Macrophage Problem in PD-L1 IHC Scoring

Synopsis

  • Digital pathology excels at PD-L1 scoring but is complicated by immune cell staining
  • Detecting macrophages in tissues is difficult because of varied morphology
  • Pathology assisted tools leveraging AI and machine learning techniques can help us detect and learn about macrophages in the context of PD-L1 immunostaining

10:30 am Speed Networking & Morning Refreshments

Synopsis

This session is fast paced aiming to provide brief introductions to as many participants at the Macrophage-Directed Therapies Summit as early on in the meeting as possible. The renowned speed networking session will be one of the most valuable hours you spend at this summit.

11:30 am DSP107, a Novel Immunotherapeutic Targeting both Innate & Adaptive Immunity

Synopsis

• Outline Dual Signaling Protein (DSP) platform technology
• Learn about the DSP107 mechanism of action targeting both CD47 whilst simultaneously activating the immune cells via the 41BBL pathway
• Discuss CD47 targeting with a differentiated PK and safety profile

12:00 pm Selective Anti-SIRPα Antibody: Next generation Myeloid Checkpoint Inhibitor

Synopsis

• Looking into OSE’s approach to targeting SIRPA instead of CD47
• Review anti-SIRPa efficacy in monotherapy and combination therapies
• Discuss translational research characterizing safety, pharmacokinetics, pharmacodynamics and preliminary efficacy in solid tumors

12:30 pm Incorporating Novel Tools to Enhance Ex Vivo Cell Manufacturing Workflows

Synopsis

    • Innovative GMP raw materials and instrumentation to streamline cell therapy manufacturing
    • Mitigating risk within scaled-up processes
    • Integrated tools to optimize macrophage CARs

12:40 pm Lunch & Networking

Repolarizing Macrophages to Stimulate Anti-Tumor Effects

2:00 pm Completing the Immunity Cycle by Developing Macrophage Immunotherapies

Synopsis

• Assess how macrophages and dendritic cells are biologically optimized to either induce or suppress an immune response
• Understand why repolarizing pro-tumorigenic macrophages has been repeatedly identified as a crucial next step for the field of immuno-oncology
• Outline how myeloid cell suppression has been fuelling the vicious cycle of the autoimmune disease
• Summarise Verseau Therapeutics’ approaches to tweaking myeloid cell functionality in human disease by targeting Macrophage Checkpoint Modulators

2:30 pm Regulating Macrophage Polarization to Create a Tumor Suppressive Environment

Synopsis

• Discuss macrophage phenotypes, the tumour microenvironment and implications for immune response and prognosis
• Review Esterase Sensitive MotifTM drugs to control polarity and lock specific phenotypes
• Explore potential targets and immuno-oncology combinations

3:00 pm Targeting Macrophages for Anti-cancer Therapy

Synopsis

• Harness the anti-tumor potential of tumor associated macrophages for cancer immunotherapy in triple negative breast cancers
• Elucidate the diversity of myeloid cells in breast cancer
• Understand the complexity of tumor macrophages in breast cancer

3:30 pm Therapeutic Approaches & Basic Research on Myeloid Immune Suppression in the Tumor Microenvironment

Synopsis

• Analyze the evidence for myeloid cell infiltrates limiting clinical responses
• Discuss the types and mechanisms of myeloid immune suppression in the TME
• Outline emerging therapeutic approaches and basic research

4:00 pm Afternoon Refreshments & Networking

4:30 pm Audience Discussion on Key Clinical Considerations for Macrophage-directed Therapies

  • Sergio Trombetta Senior Principal Scientist, Cancer Immunology & Immune Modulation, Boehringer Ingelheim

Synopsis

This session is designed for you to work in groups to network and collaborate with delegates from different companies to share your insights and overcome common challenges in the field.

Topic A - Discuss the Need for Reliable & Translatable Preclinical Models

• Review and detail current preclinical models and their
lack of reliable translation when replicating activity in human
systems

• Discuss novel strategies for testing efficacy exploring humanised mouse models and ex-vivo tumor slices and tumor dissociated cultures

Topic B - Manufacturing Considerations for Characterizing & Scaling Up Macrophage Therapies
Topic C - Improve Clinical Efficacy with Combination Therapies

5:30 pm Chair’s Closing Remarks

  • Dora Mitchell Vice President, Business Development, Carisma Therapeutics

8:30 am Chair’s Opening Remarks

  • Dora Mitchell Vice President, Business Development, Carisma Therapeutics

Macrophage Targeting Approaches

Targeting the “Don’t Eat Me Signal” to Overcome Sink Effect & Toxicity Risks

9:00 am Targeting CD47-SIRPa Myeloid Checkpoint Pathway to Enhance Innate & Adaptive Immunity Against Cancer without Hematological Toxicity

  • Hong Wan Chief Scientific Officer, ALX Oncology

Synopsis

• Discuss how ALX148, a unique CD47 blocker which is a high affinity SIRPa fusion protein linked to an inactive Fc region of human immunoglobulin, is designed to maximize the clinical benefit of antibody-based therapies and its clinical development for a broad range of tumor types
• Review preclinical studies where ALX148 bridges innate and adaptive immunity via Fc-dependent and Fc-independent mechanisms to enhance anti-tumor response in combination with targeted anti-cancer antibodies and checkpoint inhibitors with no adverse effect on CD47-expressing normal blood cells
• Understand how ALX148 is well tolerated and demonstrates antibody-like PK and complete CD47 target occupancy in cancer patients
• Discuss anti-cancer activity and translational results from Phase 1 program

9:30 am Safety, Tolerability & Efficacy of CD47 Monoclonal Antibodies in Advanced Malignancies

  • Junjian Liu Vice President, Head of Drug Discovery & Preclinical Development, Innovent Biologics

Synopsis

• Discovery of IBI188, a fully human anti-CD47 therapeutic antibody
• Outline preliminary Phase 1 clinical trial results which explore recommended doses for IBI188 in combination
• Discuss future direction in CD47 blockade

10:00 am Using Digital Pathology Tools to Solve the Macrophage Problem in PD-L1 IHC Scoring

Synopsis

  • Digital pathology excels at PD-L1 scoring but is complicated by immune cell staining
  • Detecting macrophages in tissues is difficult because of varied morphology
  • Pathology assisted tools leveraging AI and machine learning techniques can help us detect and learn about macrophages in the context of PD-L1 immunostaining

10:30 am Speed Networking & Morning Refreshments

Synopsis

This session is fast paced aiming to provide brief introductions to as many participants at the Macrophage-Directed Therapies Summit as early on in the meeting as possible. The renowned speed networking session will be one of the most valuable hours you spend at this summit.

11:30 am DSP107, a Novel Immunotherapeutic Targeting both Innate & Adaptive Immunity

Synopsis

• Outline Dual Signaling Protein (DSP) platform technology
• Learn about the DSP107 mechanism of action targeting both CD47 whilst simultaneously activating the immune cells via the 41BBL pathway
• Discuss CD47 targeting with a differentiated PK and safety profile

12:00 pm Selective Anti-SIRPα Antibody: Next generation Myeloid Checkpoint Inhibitor

Synopsis

• Looking into OSE’s approach to targeting SIRPA instead of CD47
• Review anti-SIRPa efficacy in monotherapy and combination therapies
• Discuss translational research characterizing safety, pharmacokinetics, pharmacodynamics and preliminary efficacy in solid tumors

12:30 pm Incorporating Novel Tools to Enhance Ex Vivo Cell Manufacturing Workflows

Synopsis

    • Innovative GMP raw materials and instrumentation to streamline cell therapy manufacturing
    • Mitigating risk within scaled-up processes
    • Integrated tools to optimize macrophage CARs

12:40 pm Lunch & Networking

Repolarizing Macrophages to Stimulate Anti-Tumor Effects

2:00 pm Completing the Immunity Cycle by Developing Macrophage Immunotherapies

Synopsis

• Assess how macrophages and dendritic cells are biologically optimized to either induce or suppress an immune response
• Understand why repolarizing pro-tumorigenic macrophages has been repeatedly identified as a crucial next step for the field of immuno-oncology
• Outline how myeloid cell suppression has been fuelling the vicious cycle of the autoimmune disease
• Summarise Verseau Therapeutics’ approaches to tweaking myeloid cell functionality in human disease by targeting Macrophage Checkpoint Modulators

2:30 pm Regulating Macrophage Polarization to Create a Tumor Suppressive Environment

Synopsis

• Discuss macrophage phenotypes, the tumour microenvironment and implications for immune response and prognosis
• Review Esterase Sensitive MotifTM drugs to control polarity and lock specific phenotypes
• Explore potential targets and immuno-oncology combinations

3:00 pm Targeting Macrophages for Anti-cancer Therapy

Synopsis

• Harness the anti-tumor potential of tumor associated macrophages for cancer immunotherapy in triple negative breast cancers
• Elucidate the diversity of myeloid cells in breast cancer
• Understand the complexity of tumor macrophages in breast cancer

3:30 pm Therapeutic Approaches & Basic Research on Myeloid Immune Suppression in the Tumor Microenvironment

Synopsis

• Analyze the evidence for myeloid cell infiltrates limiting clinical responses
• Discuss the types and mechanisms of myeloid immune suppression in the TME
• Outline emerging therapeutic approaches and basic research

4:00 pm Afternoon Refreshments & Networking

4:30 pm Audience Discussion on Key Clinical Considerations for Macrophage-directed Therapies

  • Sergio Trombetta Senior Principal Scientist, Cancer Immunology & Immune Modulation, Boehringer Ingelheim

Synopsis

This session is designed for you to work in groups to network and collaborate with delegates from different companies to share your insights and overcome common challenges in the field.

Topic A - Discuss the Need for Reliable & Translatable Preclinical Models

• Review and detail current preclinical models and their
lack of reliable translation when replicating activity in human
systems

• Discuss novel strategies for testing efficacy exploring humanised mouse models and ex-vivo tumor slices and tumor dissociated cultures

Topic B - Manufacturing Considerations for Characterizing & Scaling Up Macrophage Therapies
Topic C - Improve Clinical Efficacy with Combination Therapies

5:30 pm Chair’s Closing Remarks

  • Dora Mitchell Vice President, Business Development, Carisma Therapeutics